Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug name review software loaded

This article was originally published in The Tan Sheet

Executive Summary

FDA makes its Phonetic Orthographic Computer Analysis software program available for firms to check if a proposed new drug name looks or sounds like other product names or medical terminology, the agency says in a Feb. 17 Federal Register notice. The agency uses the software to identify look-alike or sound-alike drug names that could cause health care providers or patients to prescribe or use the wrong drug and cause an adverse event (1"The Tan Sheet" Oct. 27, 2008, p. 8)

You may also be interested in...



Drug Name Review Pilot Tailors Requirements For OTC Participants

OTC drug manufacturers participating in FDA's trade name pilot will be required to include consumers in their simulation safety studies and review entire labels, not only product names

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Topics

UsernamePublicRestriction

Register

PS102631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel